Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod

Executive Summary

Desmopressin's limited efficacy over placebo doesn't dissuade FDA's advisory committee, which votes 14 to 4 in favor of approval even as many suggest indication be narrowed.

You may also be interested in...



Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug

Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.

Desmopressin Battle: Ferring Asks FDA To Reject Serenity's Nocturia Drug

Serenity's SER120 should be held to the same efficacy standards as Ferring's Nocdurna, which the agency has declined to approve three times, citizen petition says.

3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca

Pfizer, Gilead, Allergan, Valeant and AstraZeneca are among the pharma and biotech companies still to report their third-quarter results. After Merck, Bristol-Myers, Lilly, Amgen, Novartis, Sanofi and others revealed their July-to-September performance, Scrip takes a look at what to expect in the weeks ahead.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel